CoChat
Sign Up
Cited by 2,050Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

Open access
Nelson, Peter T., Alafuzoff, Irina, Bigio, Eileen H., Bouras, Constantin, Braak, Heiko, Cairns, Nigel J., Castellani, Rudolph J., Crain, Barbara J. +29 more·2012·Journal of Neuropathology & Experimental Neurology
DOI 10.1097/nen.0b013e31825018f7PMC PMC3560290
Open this paper in CoChat — free accountOpen PDF

Abstract

Clinicopathologic correlation studies are critically important for the field of Alzheimer disease (AD) research. Studies on human subjects with autopsy confirmation entail numerous potential biases that affect both their general applicability and the validity of the correlations. Many sources of data variability can weaken the apparent correlation between cognitive status and AD neuropathologic changes. Indeed, most persons in advanced old age have significant non-AD brain lesions that may alter cognition independently of AD. Worldwide research efforts have evaluated thousands of human subjects to assess the causes of cognitive impairment in the elderly, and these studies have been interpreted in different ways. We review the literature focusing on the correlation of AD neuropathologic changes (i.e. β-amyloid plaques and neurofibrillary tangles) with cognitive impairment. We discuss the various patterns of brain changes that have been observed in elderly individuals to provide a perspective for understanding AD clinicopathologic correlation and conclude that evidence from many independent research centers strongly supports the existence of a specific disease, as defined by the presence of Aβ plaques and neurofibrillary tangles. Although Aβ plaques may play a key role in AD pathogenesis, the severity of cognitive impairment correlates best with the burden of neocortical neurofibrillary tangles.

AI snapshot

Written from the paper’s full text.

TL;DR

This review synthesizes clinicopathologic correlation literature on Alzheimer disease (AD) and concludes that AD neuropathologic changes—Aβ plaques and neurofibrillary tangles—are strongly linked to cognitive impairment, with neocortical neurofibrillary tangle burden correlating best with severity. It argues that Aβ plaques alone are not sufficient for advanced AD dementia and that concomitant non-AD pathologies often weaken apparent correlations.

Key findings

  • Evidence from many independent research centers supports AD as a specific disease defined by Aβ plaques and neurofibrillary tangles, but the severity of cognitive impairment correlates best with the burden of neocortical neurofibrillary tangles.
  • Aβ plaques alone do not seem sufficient for advanced clinical AD dementia; neuritic plaques correlate with antemortem cognitive impairment better than diffuse Aβ plaques, and neocortical NFTs correlate more strongly than allocortical or subcortical NFTs.
  • In a review of 11 studies comprising 555 subjects without dementia, 12 brains were Braak stage V (2.2%) and 3 were Braak stage VI (0.5%); among thousands of cases, there was no report of a thoroughly documented individual with truly “end-stage” neocortical NFT pathology who lacked antemortem cognitive impairment proximal to death.
  • Concomitant pathologies are common and contribute noise: 75% to 90% of patients older than 90 years have some degree of cerebrovascular disease pathology, and hippocampal sclerosis affects up to 20% of individuals in advanced age and correlates with cognitive impairment independently of AD.

Methods

  • Design: narrative literature review of clinicopathologic correlation (CPC) studies on AD neuropathologic changes and cognitive status, written from the perspective of neuropathologists and clinicians.
  • Data/sample: human autopsy CPC studies, including more than 40 studies assessing Aβ plaques and numerous studies assessing NFTs; highlighted large autopsy series from at least 18 different research centers, with inclusion criteria of more than 40 patients, neuropathologic assessment of both NFTs and AβPs in cerebral neocortex, broad pathologic severity, and nondichotomous correlation with cognitive status.
  • Main analysis: qualitative synthesis of study findings, discussion of sources of bias and variability, and comparison of correlations between Aβ plaques, neuritic plaques, NFTs, and antemortem cognitive impairment; no pooled meta-analysis is reported.

Limitations

  • The paper states that CPC studies face numerous potential biases: autopsy selection bias, nonrandom clinic- or hospital-based samples, concentration on middle- and upper-income whites in advantaged countries, imperfect and evolving clinical and pathologic assessments, variable time between final clinical evaluation and autopsy, competing mortality risks, and high prevalence of concurrent diseases.
  • The paper states that autopsy provides only cross-sectional data and cannot prove molecular mechanisms; pathologic assessments identify deviations from “normal” but do not prove that plaques or tangles are proximate to the ultimate neurotoxic species.
  • The text makes evident that this is a narrative review rather than a systematic review or meta-analysis, and its highlighted large-series table uses selective inclusion criteria; the authors also note that not all AD cases fall within the same spatial continuum of NFT distributions and that Braak staging masks variability in lesion density within a given stage.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1097/nen.0b013e31825018f7

Cites

359 of 359 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 279 cited sources checked · 0 supported · 0 flagged

  • Findingcitation

    There have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies.

    “In fact, there have been hints of some beneficial effects (clinical and biochemical) linked to human anti-Aβ immunotherapies (74-79).”
    Quote in the paperNot a substantial claim0 of 6 sources checked
    • cites [74] source

      Not checked in the free run.

    • cites [75] source

      Not checked in the free run.

    • cites [76] source

      Not checked in the free run.

    • cites [77] source

      Not checked in the free run.

    • cites [78] source

      Not checked in the free run.

    • cites [79] Selkoe, 2011, Resolving controversies on the path to Alzheimer's therapeutics, Nat Med source

      Not checked in the free run.

  • Findingcitation

    The density of tau-positive NPs does correlate directly and statistically independently with some degree of cognitive impairment.

    “On the other hand, the density of tau-positive NPs does correlate directly and statistically independently with some degree of cognitive impairment (105-107) (Fig. 2).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [105] source

      Not checked in the free run.

    • cites [106] source

      Not checked in the free run.

    • cites [107] source

      Not checked in the free run.

  • Findingcitation

    We are aware of no reported case of truly intact cognition despite extremely severe AD pathologic changes (i.e. widespread neocortical NFTs) measured with quantitative pathologic analysis.

    “We are aware of no reported case of truly intact cognition despite extremely severe AD pathologic changes (i.e. widespread neocortical NFTs) measured with quantitative pathologic analysis, although many persons with intact cognition have been assessed in autopsy series (33, 42, 54, 133, 142, 148, 151-166).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [33] source

      Not checked in the free run.

    • cites [42] Hof, 1996, The neuropathological changes associated with normal brain aging, Histol Histopathol

      Not checked in the free run.

    • cites [54] source

      Not checked in the free run.

  • Findingcitation

    Even in extreme old age, the presence of many neocortical NFTs correlates with antemortem cognitive decline.

    “Even in extreme old age, the presence of many neocortical NFTs correlates with antemortem cognitive decline (105, 188-191).”
    Quote in the paperSubstantial claim0 of 5 sources checked
    • cites [105] source

      Not checked in the free run.

    • cites [188] source

      Not checked in the free run.

    • cites [189] source

      Not checked in the free run.

    • cites [190] source

      Not checked in the free run.

    • cites [191] source

      Not checked in the free run.

  • Findingcitation

    Most CPC studies confirm a significant correlation between antemortem cognitive impairment and neocortical AβPs.

    “Although the study designs were diverse in CPC studies involving AβPs, most studies confirm a significant correlation between antemortem cognitive impairment and neocortical AβPs, as demonstrated by Blessed et al (254) (Fig. 3).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [254] source

      Not checked in the free run.

  • Classified as probably not a substantial claim. 21
  • May combine two claims. 53

  • Classified as probably not a substantial claim. May combine two claims.

    Findingcitation

    Tomlinson et al (1970) found that NFTs are found in both controls and demented subjects in the hippocampus, but elsewhere in the cortex were only severe or widespread in the demented; severe generalized neurofibrillary change in the cortex was not seen in any control; it seems possible that its occurrence always indicates dementia.

    “The findings reported by Tomlinson et al (38) in 1970 have been replicated many times: “[NFTs are] found in both controls and dements [demented subjects] in the hippocampus, but elsewhere in the cortex was only severe or widespread in the dements; severe generalized neurofibrillary change in the cortex was not seen in any control; it seems possible that its occurrence always indicates dementia.””
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [38] source

      Not checked in the free run.

  • May combine two claims.

    Findingcitation

    In Terry et al (1987), of 58 subjects with dementia and AD changes, 40 had 2 or more neocortical tangles per high-magnification field in frontal, temporal, and parietal lobes; 18 had no neocortical NFTs.

    “There were 58 subjects with dementia and AD changes, of which 40 had 2 or more neocortical tangles per high-magnification field in frontal, temporal, and parietal lobes; 18 had no neocortical NFTs.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [101] source

      Not checked in the free run.

  • May combine two claims.

    Findingcitation

    The plaque-only and tangle-bearing groups in Terry et al did not differ in hippocampal tangle densities and had no significant differences in brain weights, neocortical thickness, or neocortical neuron counts.

    “The cases did not differ in hippocampal tangle densities and had no significant differences in brain weights, neocortical thickness, or neocortical neuron counts.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [101] source

      Not checked in the free run.

  • May combine two claims.

    Findingcitation

    Anti-Aβ immunotherapy in individuals with mid- to late-stage clinical AD partially cleared AβPs, but this clearance did not seem to mitigate NFT formation or the inexorable disease course.

    “There have been cases in which individuals with mid- to late-stage clinical AD were administered anti-Aβ immunotherapy that partially cleared AβPs, but this clearance did not seem to mitigate NFT formation or the inexorable disease course (69-71).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [69] source

      Not checked in the free run.

    • cites [70] source

      Not checked in the free run.

    • cites [71] source

      Not checked in the free run.

  • May combine two claims.

    Findingcitation

    Both groups in Terry et al were demented and did not differ significantly on the Blessed Dementia Scale.

    “Despite this, both groups were demented and did not differ significantly on the Blessed Dementia Scale.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [101] source

      Not checked in the free run.

  • May combine two claims.

    Findingcitation

    Using data from the National Alzheimer's Coordinating Center with inclusion and exclusion criteria, NPs and NFTs tend to coexist; this corroborates earlier observations.

    “Using data from the National Alzheimer’s Coordinating Center with inclusion and exclusion criteria, as described previously (282), NPs and NFTs tend to coexist (Table 4); this corroborates earlier observations (283).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [282] source

      Not checked in the free run.

    • cites [283] source

      Not checked in the free run.

  • May combine two claims.

    Study design and conductreasoning

    Both clinical and pathologic assessments are imperfect, variably applied, and constantly evolving.

    “In sum, both clinical and pathologic assessments are imperfect, variably applied, and constantly evolving.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Both clinical and pathologic assessments are imperfect, variably applied, and constantly evolving.

  • May combine two claims.

    Interpretationnone given

    Although Aβ plaques may play a key role in AD pathogenesis, the severity of cognitive impairment correlates best with the burden of neocortical neurofibrillary tangles.

    “Although Aβ plaques may play a key role in AD pathogenesis, the severity of cognitive impairment correlates best with the burden of neocortical neurofibrillary tangles.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Study design and conductnone given

    Studies on human subjects with autopsy confirmation entail numerous potential biases that affect both their general applicability and the validity of the correlations.

    “Studies on human subjects with autopsy confirmation entail numerous potential biases that affect both their general applicability and the validity of the correlations.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Additional changes that may occur in AD brains, such as amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacuolar degeneration, neuron loss, TDP-43 proteinopathy, and neuroinflammation, may contribute to cognitive impairment but are not considered pathognomonic features of AD.

    “Additional changes that may also occur in the brains of AD patients include amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacuolar degeneration, neuron loss, TDP-43 proteinopathy, and neuroinflammation (20-26), which may contribute to cognitive impairment; however, these are not considered pathognomonic features of AD (3).”
    Quote in the paperSubstantial claim0 of 8 sources checked
    • cites [20] source

      Not checked in the free run.

    • cites [21] source

      Not checked in the free run.

    • cites [22] Masliah, 1995, Mechanisms of synaptic dysfunction in Alzheimer's disease, Histol Histopathol

      Not checked in the free run.

    • cites [23] source

      Not checked in the free run.

    • cites [24] source

      Not checked in the free run.

    • cites [25] source

      Not checked in the free run.

    • cites [26] Scheff, 2006, Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus, J Alzheimers Dis source

      Not checked in the free run.

    • cites [3] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    The tendency to dichotomize the disease and overreliance on ordinal variables may obscure important relationships.

    “The tendency to dichotomize the disease (i.e. “demented vs nondemented”) and overreliance on ordinal variables may also obscure important relationships.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Study design and conductnone given

    CPC studies rarely are a random sample of the population and clinic- and hospital-based CPCs are subject to other potential biases.

    “Furthermore, CPC studies rarely are a random sample of the population and clinic- and hospital-based CPCs are subject to other potential biases.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: CPC studies rarely are a random sample of the population.

  • May combine two claims.

    Interpretationreasoning

    Neurofibrillary degeneration restricted to subcortical sites is often subclinical, whereas widespread neocortical NFTs are almost always associated with severe cognitive impairment in more than 1 disease state.

    “As such, neurofibrillary degeneration restricted to subcortical sites is often subclinical, whereas widespread neocortical NFTs are almost always associated with severe cognitive impairment in more than 1 disease state.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationcitation

    Tau gene mutations can produce clinical dementia with NFTs; this indicates that, under some conditions, NFTs may be directly linked to the primary or at least proximal neurodegenerative changes.

    “On the other hand, tau gene mutations can produce clinical dementia with NFTs; this indicates that, under some conditions, NFTs may be directly linked to the primary or at least proximal neurodegenerative changes (29, 31, 37).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [29] source

      Not checked in the free run.

    • cites [31] source

      Not checked in the free run.

    • cites [37] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Neurofibrillary tangles are not specific for AD and are found in almost every class of brain disease and are universal (yet topographically restricted) in normal aging subjects.

    “Neurofibrillary tangles are not specific for AD (29-32); indeed, they are found in almost every class of brain disease and are universal (yet topographically restricted) in normal aging subjects (33).”
    Quote in the paperNot a substantial claim0 of 5 sources checked
    • cites [29] source

      Not checked in the free run.

    • cites [30] Arai, 2001, Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, cor-ticobasal degeneration and progressive supranuclear palsy, Acta Neu-ropathol source

      Not checked in the free run.

    • cites [31] source

      Not checked in the free run.

    • cites [32] source

      Not checked in the free run.

    • cites [33] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisenone given

    There is no universally accepted definition of a neuritic plaque.

    “This subset of AβPs is a hallmark of the current diagnostic criteria for AD, although there is no universally accepted definition of a NP.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationcitation

    The concordance of genetics and Aβ deposition is aligned with CPC studies that indicate that AβPs may be a temporally 'upstream' feature of the neocortical disease, with the caveats that brainstem and medial temporal lobe pretangles and NFTs are seen in subjects without Aβ deposition in all age categories.

    “The concordance of genetics and Aβ deposition is aligned with CPC studies that indicate that AβPs may be a temporally “upstream” feature of the neocortical disease, with the caveats that brainstem and medial temporal lobe pretangles and NFTs are seen in subjects without Aβ deposition in all age categories (33, 39, 44).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [33] source

      Not checked in the free run.

    • cites [39] source

      Not checked in the free run.

    • cites [44] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    AβPs are extracellular and are found in a high proportion of all elderly persons but are not universal.

    “In contrast to NFTs, AβPs are extracellular (45, 46) and are found in a high proportion of all elderly persons but are not universal (44, 47, 48).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [45] source

      Not checked in the free run.

    • cites [46] source

      Not checked in the free run.

    • cites [44] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Both the density and the neuroanatomic localization of NFTs are important parameters in AD neuropathology.

    “Both the density and the neuroanatomic localization of NFTs are important parameters in AD neuropathology.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

    Interpretationreasoning

    A simplistic conceptualization of 'plaques and tangles' does not adequately reflect the complexity of the biochemical changes in the brains of patients with AD.

    “It must be acknowledged that a simplistic conceptualization of “plaques and tangles” does not adequately reflect the complexity of the biochemical changes in the brains of patients with AD.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    AβPs, in the absence of any other neurodegenerative disease lesions or other pathologies, are not a sufficient substrate for severe dementia and thus do not constitute 'advanced AD pathologic changes.'

    “It is clear, as mentioned previously, that AβPs, in the absence of any other neurodegenerative disease lesions or other pathologies, are not a sufficient substrate for severe dementia and thus do not constitute “advanced AD pathologic changes.””
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationcitation

    There are multiple reasons why anti-Aβ clinical trials may have failed, including the late timing of the therapy.

    “There are multiple reasons why these trials may have failed, including the late timing of the therapy. Thus, conclusions drawn from these trials may be premature (72, 73).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [72] source

      Not checked in the free run.

    • cites [73] Roher, 2011, Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient, J Alzheimers Dis source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Dementia, even one that may be clinically similar to probable AD, may be present without AD pathologic changes; this is simply not AD, but presumably one among many other diseases that cause dementia.

    “As for Assertion 2, it is true that dementia, even one that may be clinically similar to probable AD, may be present without AD pathologic changes; this is simply not AD, but presumably one among many other diseases that cause dementia (e.g. hippocampal sclerosis or vascular dementia).”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S4 (based). May combine two claims.

    Interpretationreasoning

    These patterns of brain changes indicate specific features that can be correlated with clinical parameters, modeled to understand disease mechanisms, and targeted for therapeutics.

    “These patterns of brain changes indicate specific features that can be correlated with clinical parameters, modeled to understand disease mechanisms, and targeted for therapeutics.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductreasoning

    Because autopsies provide only cross-sectional data, they cannot prove mechanism.

    “Because autopsies provide only cross-sectional data, they cannot prove mechanism.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationcitation

    AβPs and NFTs are the hallmark features of AD but do not develop in the human brain according to the same temporal or anatomic pattern.

    “Thus, AβPs and NFTs are the hallmark features of AD but do not develop in the human brain according to the same temporal or anatomic pattern (60, 61).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [60] source

      Not checked in the free run.

    • cites [61] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    Peptides and higher-order aggregates derived from products of APP and MAPT genes can potentially lead to combinations of neuroprotective and toxic attributes.

    “Thus, peptides and higher-order aggregates derived from products of APP and MAPT genes can potentially lead to combinations of neuroprotective and toxic attributes.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationcitation

    Dense and extensive neocortical NFTs are very consistently associated with dementia and are required to constitute high burden of AD neuropathologic change.

    “In contrast, dense and extensive neocortical NFTs are very consistently associated with dementia and thus, according to new diagnostic criteria, these are required to constitute high burden of AD neuropathologic change (3).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [3] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    The toxicity of oligomeric forms of tau and Aβ peptides could be connected with biochemical changes that also produce NPs and NFTs; thus, the oligomeric species may be directly related to the neuropathology, although they are not exactly correlated.

    “The toxicity of oligomeric forms of tau and Aβ peptides could be connected with biochemical changes that also produce NPs and NFTs; thus, the oligomeric species may be directly related to the neuropathology, although they are not exactly correlated (90-95).”
    Quote in the paperNot a substantial claim0 of 6 sources checked
    • cites [90] source

      Not checked in the free run.

    • cites [91] Jin, 2011, Soluble amyloid {β}-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration, Proc Natl Acad Sci U S A source

      Not checked in the free run.

    • cites [92] Gadad, 2011, Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-β peptide, J Alzheimers Dis source

      Not checked in the free run.

    • cites [93] source

      Not checked in the free run.

    • cites [94] source

      Not checked in the free run.

    • cites [95] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisenone given

    Both tau phosphorylation and Aβ peptide generation are seen in 'normal' brains.

    “Since both tau phosphorylation and Aβ peptide generation are seen in “normal” brains, some contend that there are probably beneficial and adaptive aspects to these molecular processes.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationnone given

    When modern pathologic methods are used, severe cognitive impairment associated only with diffuse AβPs in the brain at autopsy is rare and has an unknown relationship to AD.

    “When modern pathologic methods are used, severe cognitive impairment associated only with diffuse AβPs in the brain at autopsy is rare and has an unknown relationship to AD.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Premisecitation

    The median life expectancy in Western countries is approximately 79 years.

    “The median life expectancy in Western countries is approximately 79 years (141).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [141] Central Intelligence Agency. The World Factbook. Washington, DC: Central Intelligence Agency, 2008

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Some individuals with intact or subtly diminished cognitive abilities have hippocampal and/or amygdala NFTs (Braak stages III-IV) with few or no AβPs; these represent approximately 5% of cases in some large autopsy series.

    “There are also some individuals with intact or subtly diminished cognitive abilities whose brains harbor hippocampal and/or amygdala NFTs (Braak stages III–IV) with few or no AβPs; these represent approximately 5% of cases in some large autopsy series (41).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [41] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    Subtle cognitive impairment may be associated with diffuse AβPs, indicating that these lesions may play a direct role in incipient AD, although a direct role of diffuse Aβ plaques without tau pathology has not been proven.

    “Subtle cognitive impairment may be associated with diffuse AβPs, indicating that these lesions may play a direct role in incipient AD (54), although a direct role of diffuse Aβ plaques without tau pathology has not been proven.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [54] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    Diffuse AβPs may be associated with cerebral amyloid angiopathy, which could produce impairments separately.

    “Furthermore, diffuse AβPs may be associated with cerebral amyloid angiopathy, which could produce impairments separately (103, 104), although see Nelson et al (105).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [103] source

      Not checked in the free run.

    • cites [104] source

      Not checked in the free run.

    • cites [105] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    The current revision of the NIA-AA guidelines stipulates that subjects with moderately dense neuritic AβPs may be regarded as having an intermediate level of AD neuropathologic change and that other potential contributors to cognitive impairment and dementia should be sought.

    “The current revision of the National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of AD stipulate that subjects with moderately dense neuritic AβPs may be regarded as having an intermediate level of AD neuropathologic change and that other potential contributors to cognitive impairment and dementia should be sought (3).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [3] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    This modeled expectation is precisely the observation reported by one of the largest autopsy series to date and is well supported by AD biomarker studies.

    “Indeed, this is precisely the observation reported by one of the largest autopsy series to date (142) and is well supported by AD biomarker studies (143-145).”
    Quote in the paperNot a substantial claim0 of 4 sources checked
    • cites [142] source

      Not checked in the free run.

    • cites [143] source

      Not checked in the free run.

    • cites [144] source

      Not checked in the free run.

    • cites [145] Sonnen, 2010, Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia, J Alzheimers Dis source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Using these data, an 'average' person dying at age 79 has an approximately 15% likelihood of having been diagnosed clinically with ADD, but an approximately 30% to 40% chance of harboring significant AD neuropathologic changes.

    “Thus, using these data, we can deduce confidently that an “average” person dying at age 79 has an approximately 15% likelihood of having been diagnosed clinically with ADD, but an approximately 30% to 40% chance of harboring significant AD neuropathologic changes (otherwise, the prevalence of ADD could not reach approximately 30%–40% by age 95).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In this condition, the NFTs comprise tau isoforms similar to those of classic AD, but these subjects do not have the same distribution of APOE genotypes as subjects with AD.

    “In this condition, the NFTs comprise tau isoforms similar to those of classic AD, but these subjects do not have the same distribution of APOE genotypes as subjects with AD (118).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [118] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    In most community-based autopsy series, non-AD tauopathies constitute approximately 1% of dementia cases.

    “In most community-based autopsy series, non-AD tauopathies constitute approximately 1% of dementia cases (108-115) (but see Noda et al [116]).”
    Quote in the paperNot a substantial claim0 of 9 sources checked
    • cites [108] source

      Not checked in the free run.

    • cites [109] source

      Not checked in the free run.

    • cites [110] source

      Not checked in the free run.

    • cites [111] Schneider, 2009, The neuropathology of older persons with and without dementia from community versus clinic cohorts, J Alzheimers Dis source

      Not checked in the free run.

    • cites [112] source

      Not checked in the free run.

    • cites [113] source

      Not checked in the free run.

    • cites [114] source

      Not checked in the free run.

    • cites [115] source

      Not checked in the free run.

    • cites [116] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The prevalence of dementia due to AD, as judged by clinicians, doubles every half-decade after age 65; thus, approximately 30% to 40% of living 95-year-old patients receive the diagnosis of ADD.

    “The prevalence of dementia due to AD, as judged by clinicians, doubles every half-decade after age 65; thus, approximately 30% to 40% of living 95-year-old patients receive the diagnosis of ADD (126-128).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [126] source

      Not checked in the free run.

    • cites [127] Aronson, 1991, Dementia, Age-dependent incidence, prevalence, and mortality in the old old. Arch Intern Med

      Not checked in the free run.

    • cites [128] Katzman R Kawas C . The epidemiology of dementia and Alzheimer disease. In: Terry RD , ed. Alzheimer Disease. New York, NY: Raven Press, Ltd, 1994:105–22

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Schizophrenia in elderly patients is associated with dementia, although the underlying basis of this dementia is enigmatic.

    “A notable example of this is schizophrenia, which, in elderly patients, is associated with dementia, although the underlying basis of this dementia is enigmatic (174-176).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [174] source

      Not checked in the free run.

    • cites [175] source

      Not checked in the free run.

    • cites [176] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Cerebrovascular disease is the most prevalent non-AD pathologic diagnosis in the brains of the advanced aged and is directly relevant to any CPC study related to dementia.

    “Cerebrovascular disease (CVD) is the most prevalent non-AD pathologic diagnosis in the brains of the advanced aged and is directly relevant to any CPC study related to dementia.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationcitation

    It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; data support the modeled expectations.

    “It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [44] source

      Not checked in the free run.

    • cites [142] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Normal pressure hydrocephalus is another poorly understood cause of dementia that may lack AD pathologic changes.

    “Normal pressure hydrocephalus is another poorly understood cause of dementia that may lack AD pathologic changes (177, 178).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [177] Leinonen V Koivisto AM Savolainen S . Post-mortem findings in 10 patients with presumed normal pressure hydrocephalus and review of the literature. [published online ahead of print February 10, 2012] Neuropathol Appl Neurobiol

      Not checked in the free run.

    • cites [178] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    These 'survivors' represent a small fraction of the human population with underrepresentation of APOE ε4 allele.

    “However, not all studies are in agreement on this point (185, 186); these “survivors” represent a small fraction of the human population with underrepresentation of APOE ε4 allele (187).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [187] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    AβPs may be a key pathologic factor in AD without equating with the clinical features of ADD.

    “In the same way, AβPs may be a key pathologic factor in AD without equating with the clinical features of ADD.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    It has been suggested that the pathogenetic effect of AβP-related substances may be mediated by 'seeding' neurofibrillary pathology.

    “Owing in part to the scarcity of neocortical NFTs in the absence of AβPs, and the relatively modest apparent direct impact of AβPs on cognition, it has been suggested that the pathogenetic effect of AβP-related substances may be mediated by “seeding” neurofibrillary pathology (46, 88, 189, 264, 265).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [46] source

      Not checked in the free run.

    • cites [88] source

      Not checked in the free run.

    • cites [189] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    The number of AβPs might plateau (or at least the rate of increase flatten out), leading to a 'ceiling effect' relatively early in disease process that confounds linear correlations between plaque number and severity of cognitive change.

    “For this reason, the number of AβPs might plateau (or at least the rate of increase flatten out), leading to a “ceiling effect” relatively early in disease process that confounds linear correlations between plaque number and severity of cognitive change (253).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [253] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

    Interpretationcitation

    The profound impact of CVD on studies pertinent to cognition in the elderly seems to be underappreciated in dementia research.

    “Nevertheless, the profound impact of CVD on studies pertinent to cognition in the elderly seems to be underappreciated in dementia research (208-210).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [208] source

      Not checked in the free run.

    • cites [209] Thal, 2003, Vascular pathology in Alzheimer disease: Correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline, J Neuropathol Exp Neurol source

      Not checked in the free run.

    • cites [210] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In more advanced Alzheimer disease, the neuroanatomic distribution of neurofibrillary tangles correlates with the location at which neurons die and with the cognitive domains affected in patients with Alzheimer disease dementia.

    “In more advanced disease, the neuroanatomic distribution of NFTs correlates both with the location at which neurons die (302-305) and with the cognitive domains affected in patients with ADD.”
    Quote in the paperSubstantial claim0 of 4 sources checked
    • cites [302] source

      Not checked in the free run.

    • cites [303] source

      Not checked in the free run.

    • cites [304] source

      Not checked in the free run.

    • cites [305] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Interpretationcitation

    As AD progresses, the NFTs become numerous in locus coeruleus which may suggest the same pathogenetic process is becoming more severe.

    “As AD progresses, the NFTs become numerous in locus coeruleus which may suggest the same pathogenetic process is becoming more severe (301).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [301] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    The abnormal NP-contacting dendrites and axons contain pathologic tau fibrils identical to those seen in NFTs, with loss of adjacent synapses.

    “The abnormal NP-contacting dendrites and axons contain pathologic tau fibrils identical to those seen in NFTs (244, 273), with loss of adjacent synapses (274, 275).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [244] source

      Not checked in the free run.

    • cites [273] source

      Not checked in the free run.

    • cites [274] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    Dystrophic axons from completely different afferent sources, expressing distinct neurotransmitters, have been shown to be present in particular NPs, which strongly implies that toxicity is directed from the (extracellular) plaque to the radially arranged intracellular neurites.

    “Dystrophic axons from completely different afferent sources, expressing distinct neurotransmitters, have been shown to be present in particular NPs (276, 277), which strongly implies that toxicity is directed from the (extracellular) plaque to the radially arranged intracellular neurites.”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [276] source

      Not checked in the free run.

    • cites [277] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing). May combine two claims.

    Interpretationreasoning

    This process may be synergistic or identical to the stimuli that could promote NFTs in human brains.

    “This process may be synergistic or identical to the stimuli that could promote NFTs in human brains.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Some evidence exists for neurofibrillary tangle turnover, neuronal shrinkage, and/or non-neurofibrillary-tangle cell death mechanisms.

    “Thus, some evidence exists for NFT “turnover,” neuronal shrinkage, and/or non-NFT cell death mechanism(s).”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Neurofibrillary tangles are quantified with certainty only at autopsy.

  • Probably not a substantial claim: may not pass S4 (based).

    Premisenone given

    Concomitant pathologies are very common in aging brains.

    “Concomitant pathologies are very common in aging brains.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    A patient lacking Alzheimer disease pathologic diagnosis at autopsy despite biomarker positivity is not an Alzheimer disease case and suggests the biomarker has imperfect specificity.

    “A patient lacking AD pathologic diagnosis at autopsy, despite “biomarker positivity,” is not an AD case and suggests the biomarker has imperfect specificity.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Premisenone given

    Neuritic plaques combine extracellular amyloid-beta deposition and intracellular neurofibrillary tau protein pathology.

    “Neuritic plaques combine extracellular Aβ deposition and intracellular neurofibrillary (tau protein) pathology.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisenone given

    There are still no recognized biomarker-based criterion standards for a large number of other neurodegenerative tauopathies, synucleinopathies, and vascular brain changes.

    “Indeed, there are still also no recognized biomarker-based criterion standards for a large number of other neurodegenerative tauopathies, synucleinopathies, and vascular brain changes.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductnone given

    Pathologic assessments cannot prove molecular mechanisms; instead, they identify and describe deviations from what is recognized as normal.

    “Pathologic assessments cannot prove molecular mechanisms; instead, they identify and describe deviations from what is recognized as “normal.””
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Because cognitive impairment in aging may be attributed to many different conditions other than Alzheimer disease, current Alzheimer disease biomarkers are limited to predicting which patients may become cognitively impaired with neocortical amyloid-beta plaques and neurofibrillary tangles, rather than just predicting cognitive impairment alone.

    “Because cognitive impairment in aging may be attributed to many different conditions other than AD, current biomarkers for AD are limited to predicting which patients may become cognitively impaired with neocortical AβPs and NFTs, rather than just predicting cognitive impairment alone.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Premisereasoning

    Until a non-autopsy method becomes available, neuropathologic examination remains the criterion standard for Alzheimer disease definition.

    “However, until such a method becomes available, neuropathologic examination remains the criterion standard for disease definition.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisereasoning

    Hippocampal atrophy is visualized on magnetic resonance imaging in both Alzheimer disease and hippocampal sclerosis patients and is therefore not a distinct Alzheimer disease biomarker.

    “For example, hippocampal atrophy is visualized on magnetic resonance imaging in both AD and hippocampal sclerosis patients and is therefore not a distinct AD biomarker.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Up to 20% of individuals in advanced age are affected by hippocampal sclerosis that correlates with cognitive impairment independently of Alzheimer disease pathologic diagnosis.

    “This is an important consideration because up to 20% of individuals in advanced age are affected by hippocampal sclerosis that correlates with cognitive impairment independently of AD pathologic diagnosis (105, 211, 321-323).”
    Quote in the paperSubstantial claim0 of 5 sources checked
    • cites [105] source

      Not checked in the free run.

    • cites [211] source

      Not checked in the free run.

    • cites [321] source

      Not checked in the free run.

    • cites [322] source

      Not checked in the free run.

    • cites [323] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Although the density of neocortical neurofibrillary tangles and neuritic amyloid-beta plaques on autopsy correlates with the severity of cognitive dysfunction, this does not prove that these pathologic hallmarks are proximate to the ultimate neurotoxic species.

    “Although the density of neocortical NFTs and neuritic AβPs on autopsy correlate with the severity of cognitive dysfunction, and the observed results align with a plausible hypothesis, this does not prove that these pathologic hallmarks are proximate to the ultimate neurotoxic species.”
    Quote in the paperSubstantial claim
66 of 66

  • The paper relies on this without support.

    Autopsy is required for definitive AD diagnosis.

    “Autopsy is required for definitive AD diagnosis, yet autopsy rates are generally low and autopsy inevitably confers a selection bias.”

  • The paper relies on this without support.

    Autopsy rates are generally low.

    “Autopsy is required for definitive AD diagnosis, yet autopsy rates are generally low and autopsy inevitably confers a selection bias.”

  • The paper relies on this without support.

    CPC studies rarely are a random sample of the population.

    “Furthermore, CPC studies rarely are a random sample of the population and clinic- and hospital-based CPCs are subject to other potential biases.”

  • The paper relies on this without support.

    Most prior studies have concentrated on middle- and upper-income whites.

    “Most prior studies have been performed in countries with the most advantageous socioeconomic conditions and have concentrated on middle- and upper-income whites.”

  • The paper relies on this without support.

    Both clinical and pathologic assessments are imperfect, variably applied, and constantly evolving.

    “In sum, both clinical and pathologic assessments are imperfect, variably applied, and constantly evolving.”

  • The paper relies on this without support.

    Neurofibrillary tangles are quantified with certainty only at autopsy.

    “As with AβPs, NFTs are quantified with certainty only at autopsy.”
6 of 6

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tau pathology is linked to cognitive decline, may progress more rapidly than Aβ accumulation, and correlates with neuroinflammation, making it a valuable prognostic marker.

    “Numerous studies have linked tau pathology to cognitive decline, with some evidence suggesting it progresses more rapidly than Aβ accumulation and correlates with neuroinflammation, making it a valuable prognostic marker [20, 25–28].”

    From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [26]

    The 'Overview of Specific Large Autopsy Series' says neocortical neurofibrillary-tangle density correlates strongly with antemortem cognitive status, supporting the link between tau pathology and cognitive impairment. The sections on NFTs and Aβ plaques describe different timing and anatomical patterns, not a faster rate of tau progression; the passages do not establish a tau–neuroinflammation correlation or validate tau as a prognostic marker. Page numbers are unavailable in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • VEEV neuropathology shares similarities with Alzheimer's disease, including increased astrogliosis, glial nodules, and pathological indicators of neuroinflammation including perivascular cuffing.

    “VEEV neuropathology shares similarities with AD, a widespread cognitive disorder of aging, including increased astrogliosis, glial nodules, and pathological indicators of neuroinflammation including perivascular cuffing (Nelson et al., 2012; Williams et al., 2023).”

    From Arbovirus infection increases the risk for the development of neurodegenerative disease pathology in the murine model (2024) · cites this paper as Nelson et al., 2012

    The section on AD histopathologic hallmarks lists neuroinflammation among changes that may occur in AD, and the Summary and Conclusions links AD pathology with cognitive impairment in aging brains (page numbers unavailable). The copy does not establish a similarity with VEEV or identify increased astrogliosis, glial nodules, or perivascular cuffing as shared features. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Variance in distribution and burden of tauopathy in AD is closely associated with clinical phenotype, cognitive deficit, and rate of cognitive decline.

    “Variance in the distribution and burden of tauopathy in AD is closely associated with the clinical phenotype, 13 cognitive deficit, 14 and rate of cognitive decline. 15”

    From Alzheimer's disease and its progression reduce pyramidal cell gain and connectivity (2025) · cites this paper as [14]

  • AD is characterized by intraneuronal neurofibrillary tangles of hyperphosphorylated tau and extracellular Aβ plaques.

    “Histopathologically, AD is characterized by the formation of intraneuronal neurofibrillary tangles consisting of the hyperphosphorylated microtubule protein, tau, and extracellular deposits of plaques of amyloid-β (Aβ), a breakdown product of the transmembrane amyloid precursor protein (APP) [241]”

    From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [241]

  • NFT pathology closely correlates with neurodegeneration and cognitive decline.

    “Recent studies suggest that NFT pathology closely correlates with neurodegeneration and cognitive decline [1, 2].”

    From Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology (2016) · cites this paper as [2]

Cites

Flagged first, then by citations

10 of the 369 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

  1. Terry RD Masliah E Hansen LA . Structural basis of the cognitive alterations in Alzheimer disease. In: Terry RD Katzman R Bick KL , eds. Alzheimer Disease. New York, NY: Raven Press, 1994:179–96
  2. Schneider, 2009, The neuropathology of older persons with and without dementia from community versus clinic cohorts, J Alzheimers Dis, 18, 691, 10.3233/jad-2009-1227 · DOI · Paper page
  3. 10.1093/brain/awr053 · DOI · Paper page
  4. 10.1097/60.10.946 · DOI
  5. 10.1093/brain/awr308 · DOI · Paper page
  6. 10.1097/60.11.1075 · DOI

Cited by

Sorted by citations

Related

Authors
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., Duyckaerts, C., Frosch, M. P., Haroutunian, V., Hof, P. R., Hulette, C. M., Hyman, B. T., Iwatsubo, T., Jellinger, K. A., Jicha, G. A., Kövari, E., Kukull, W. A., Leverenz, J. B., Love, S., Mackenzie, I. R., Mann, D. M., Masliah, E., McKee, A. C., Montine, T. J., Morris, J. C., Schneider, J. A., Sonnen, J. A., Thal, D. R., Trojanowski, J. Q., Troncoso, J. C., Wisniewski, T., Woltjer, R. L., & Beach, T. G.
Affiliations
  • University of Kentucky (US)
  • Uppsala University (SE)
  • Northwestern University (US)
  • University of Geneva (CH)
  • University of Maryland, Baltimore (US)
  • University of British Columbia (CA)
  • Albert Einstein College of Medicine (US)
  • Harvard University (US)
  • Boston University (US)
  • Rush University Medical Center (US)
Corresponding author
Nelson, Peter T.
ORCID
Venue
Journal of Neuropathology & Experimental Neurology
Publisher
Oxford University Press (OUP)
Published
2012-05
Volume
71
Issue
5
Pages
362-381
ISSN
  • 0022-3069 (ISSN-L)
  • 1554-6578
DOI
10.1097/nen.0b013e31825018f7
PMC
PMC3560290
OpenAlex
W2074274706
Semantic Scholar
bce678baa6d56ad7c06197507d7903b6c7619507
Cited by
2,050
References
369
Citations by year
2026: 115 · 2025: 153 · 2024: 166 · 2023: 161 · 2022: 213 · 2021: 205 · 2020: 194 · 2019: 179 · 2018: 139 · 2017: 134 · 2016: 108 · 2015: 95 · 2014: 98 · 2013: 72 · 2012: 17
FWCI
12.22
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuropathology & Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Bristol Research (University of Bristol) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
  • Alzheimer's Association
  • Alzheimer Forschung Initiative
  • Alzheimer's Society
  • Deutsche Forschungsgemeinschaft
  • Medical Research Council
  • National Institute on Aging (AG-028383, AG 016976, AG-15819, AG13854, AG 10161, R01AG035071, AG-02219, AG 05136, P30AG028383, AG008017, U01AG006781, AG 05138, U01AG016976, P50AG005138, AG-06647, AG035071, P30AG010124, AG 05681, R01AG015819, P30AG008017, AG-10124, P30AG010161, R37AG022102, R01AG006647, P30AG008051, AG 08051, P50AG005681, R01AG022102, P50AG005136, P30AG013854, U19AG010483, R37AG006647, R01AG020245, P01AG002219, RF1AG015819)
  • National Institute of Neurological Disorders and Stroke (R01NS073502)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, clinicopathological correlation, cognitive impairment, amyloid plaques, neurofibrillary tangles, disease severity
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition Disorders, Humans, Statistics as Topic, Amyloid beta-Peptides, Neurofibrillary Tangles, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review